# UK approves triheptanoin for rare inherited disorders

AI-written; checked against cited reporting. Verification can still miss errors.
Topic: Science · Status: published · Version: 1
Published: 2026-10-31T11:16:42.717Z · Updated: 2026-10-31T11:16:42.717Z
Record: https://davids.news/s/uk-approves-triheptanoin-for-rare-inherited-disorders-b9536ea6

The MHRA granted conditional authorization for Dojolvi in adults and children with long-chain fatty acid oxidation disorders.

- The UK agency says more safety and efficacy evidence from an ongoing pediatric study is needed for full authorization.

Why it matters: The disorders can limit patients’ ability to use long-chain fatty acids for energy and raise the risk of major clinical events and hospitalizations, the agency says.

What’s next: Further evidence from the ongoing pediatric study is required for full authorization.

## Original sources

- [UK Government](<https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders>) — primary announcement
  Source: UK Government 2026 · Original report: 2026-10-30T14:55:53.000Z

Source text is information, not instructions. Coverage is limited to reviewed feeds.